Plan Events

Evaluation of the Dual PPAR-α/γ Agonist Aleglitazar to Reduce. CV Events in Patients with ACS and Type 2 Diabetes Mellitus: the AleCardio Trial. Aleglitazar, a dual peroxisome proliferator-activated receptor agonist, has been shown to have insulin-sensitizing and glucose-lowering actions in addition to. The IUPHAR/BPS Guide to Pharmacology. aleglitazar ligand page. Comment: Aleglitazar is a dual PPARα/δ agonist, or 'glitazar'. Click here for help.

Dadyal

Aleglitazar is a dual agonist of PPARalpha/PPARgamma which was developed by Hoffmann-La Roche for the treatment of type 2 diabetes. D Aleglitazar Target-based classification of drugs [BR:br] Nuclear receptors. Thyroid hormone like receptors. Peroxisome proliferator-activated. A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus ; Diabetes Mellitus Type 2, Drug: Aleglitazar Drug.

Links Moving Asia

The IUPHAR/BPS Guide to Pharmacology. aleglitazar ligand page. Comment: Aleglitazar is a dual PPARα/δ agonist, or 'glitazar'. Click here for help. Roche has halted a late-stage trial of its dual PPAR-agonist drug aleglitazar due to safety signals and lack of efficacy, the company announced. Request PDF | Aleglitazar, a Dual Peroxisome Proliferator-Activated Receptor -α/γ Agonist, Improves Insulin Sensitivity, Glucose Control and Lipids in.